GBP2 serves as a positive prognostic marker in breast cancer, where it correlates with reduced tumor growth, heightened paclitaxel sensitivity, and improved survival—particularly valuable for triple-negative subtypes—detectable in blood as a minimally invasive tool via ELISA or mass spectrometry, offering a practical diagnostic approach [36,38]. This evidence concerns the gene GBP2 and breast carcinoma.